Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 Slide Shows
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
CES 2010 Coverage 

Follow Us
RTTNews on Twitter RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube


Font Down Font Up
Cell Therapeutics Posts Wider Loss In Q3 - Update
11/5/2009 3:47 AM ET

RELATED NEWS
FDA Postpones Panel Meeting To Review Cell Therapeutics' Drug Due To Extreme Weather - Update
Cell Therapeutics Says FDA Postpones ODAC Meeting To Review Pixantrone Due To Severe Weather Conditions - Quick Facts
Cell Therapeutics - Facing The Big Test
Cell Therapeutics To Present At The 28th Annual JP Morgan Healthcare Conference At 5:00 PM, ET
Cell Therapeutics To Sell $30 Mln Of Preferred Stock And Warrants To Institutional Investors - Quick Facts

Trade CTIC now with
(RTTNews) - Biopharmaceutical company Cell Therapeutics, Inc. (CTIC: News ) Thursday reported a wider net loss for the third quarter of fiscal 2009, as there were no product sales in the quarter.

For the third quarter, net loss attributable to shareholders widened to $48.84 million from a loss of $47.65 million in the prior-year period. On a per share basis, Cell Therapeutics' net loss narrowed to $0.09 from $2.83 last year, as the company used 527.20 million shares and 16.81 million shares to calculate loss per share in the third quarter of 2009 and 2008, respectively.

The Seattle, Washington-based company said the quarter's net loss included non-cash expenses of $11.4 million in equity-based compensation expense, $6.0 million in connection with milestone payment modification expense and $13.8 million preferred stock deemed dividend expenses.

The modification to milestone expense relates to the agreement to issue $6.0 million of shares of the company's common stock to Systems Medicine, Inc. shareholders, Cell Therapeutics added.

Total revenues for the period plummeted to $20 thousand from $2.60 million in the third quarter of fiscal 2008.

There were no revenues from product sales in the quarter compared to $2.58 million generated last year. Revenues from license and contract for the three-month period were $20 thousand, flat with the previous year.
Total operating expenses for the period increased to $27.09 million from $20.46 million in the last year quarter. During the period, Cell Therapeutics incurred a one-time charge of $178 thousand with regard to restructuring and related gain on asset sale. Research and development expenses for the quarter dropped 33% to $7.6 million from $11.3 million in the corresponding period prior year.

For the nine-month period, attributable net loss narrowed to $89.39 million from $161.57 million a year earlier. On a per share basis, net loss was $0.21 as compared with $13.68 in the 2008-year period. Year-to-date revenues plunged to $60 thousand from $8.88 million in the previous-year period.

Looking ahead, chief executive officer James Bianco said, "With the recent developments and progress we are making in advancing pixantrone through its New Drug Application (NDA) review process we expect the next 3 to 6 months to be an exciting and transformative period for the Company."

In Wednesday's regular trading session, CTIC closed trading on the Nasdaq at $0.97 per share. In the 52-week period, the shares have been trading in a range of $0.05 to $2.23.

To receive FREE breaking news email alerts for Cell Therapeutics Inc. and others in your portfolio


by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print           Follow Us RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

     
Top Stories
EOG Resources Q4 Profit Down 13%; Raises Quarterly Dividend - Update

UDR Q4 FFO Declines; Guides FY10

Baidu Q4 Profit Up 48.2%; Guides Q1 Revenue Above Estimates

IMS Health Profit Declines 27%

CareFusion Q2 Profit Declines; Revises Up FY10 View - Update

Earnings
EOG Resources Q4 Profit Down 13%; Raises Quarterly Dividend - Update

Taiga Building Products Swings To Profit In Q3 - Quick Facts

BHP Billiton Half-year Attributable Profit Jumps; Revenue Declines 17.5%; Economic Outlook Cautious - Quick Facts

Ridley Q2 Profit Rises - Quick Facts

Emcore Q1 Loss Narrows; Guides Q2 Revenues - Quick Facts

US Market Commentary
Stocks Post Strong Gains Amid Prospective Greece Bailout - U.S. Commentary

Stocks Hovering Near Highs In Mid-Afternoon Trading - U.S. Commentary

TSX Jumps On Greece Rescue Rumors

Stocks Building On Strong Gains In Early Afternoon Trading - U.S. Commentary

Stocks Give Back Ground But Remain Mostly Higher - U.S. Commentary

US Economic News
ABC News Consumer Confidence Improves Slightly

Reports: Germany Yet To Decide On Possible Aid Package To Greece

Bernanke Hearing Postponed Due To Weather

Wholesale Inventories Show Unexpected Decrease In December

Wholesale Inventories Fell 0.8% In December

Political News
Nigerian Vice-President Goodluck Jonathan Assumes Presidential Powers

Obama: International Community Moving Quickly Towards Iran Sanctions

Obama Calls For Give And Take With GOP

EU Parliament Approves New European Commission

Rubio Endorsed By Conservative Leader In Florida Senate Primary




 
President Urges Congressional Leaders To Negotiate
02/09/10 05:23
Wall Street Bounces Back Tuesday
02/09/10 05:11
Stocks Sharply Higher In Mid-Day Trading
02/09/10 02:44
 

Today's Stocks to Watch
PSOF - Pansoft Company Limited
RBCN - RUBICON TECHNOLOGY,
NTUR.OB - Natural Blue Resources, Inc.
SNSS - Sunesis Pharmaceuticals Inc.
SITO.OB - Single Touch Systems Inc.
MKTX - MARKETAXESS HOLDINGS INC


Hopes of Diffusion of European Debt Crisis May Lead to Some Bargain Hunting
The major U.S. index futures are pointing to a higher opening on Tuesday, with European debt concerns receding following indications from European Commission officials that they may step in to save Greece from getting mired in the debt crisis. Commodity prices are extending their gains and this coupled with the oversold levels of the markets may support a bounce back. Given the fact that the wholesale inventories report to be released after the markets close is not market moving, the markets may derive support from hopes that the economic revival may not lose steam despite the surrounding uncertainty.
The Week In Washington  Lawmakers spent a busy week in Washington discussing the recently unveiled Fiscal Year 2011 budget, and the Democrats new jobs agenda

 

Copyright © 2010 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service| How To Use RTTNews.com| Advertise| Privacy| Buy Content | RSS